Moderna Q2 2026: A Quietly Determined Quarter as Regulatory Catalysts Harvest in the Wings

Key takeaways

• Second-quarter revenue reported around $145 million, up slightly from $142 million a year earlier; US revenue about $87 million and international $58 million.
• GAAP net loss of roughly $0.8 billion for the quarter, with GAAP EPS of about $(1.97) per share.
• Cost of sales totaled about $93 million, with notable items including $41 million of inventory write-downs, $23 million of unutilized manufacturing capacity costs, and $11 million of third‑party royalties. Costs declined ~22% versus the prior year due to productivity gains and operational efficiencies.
• R&D spend totaled $651 million, a 7% year-over-year decline as Moderna winds down several late-stage programs.
• SG&A expenses were $216 million, a 6% decrease from the prior year.
• Non-material income taxes due to a global valuation allowance against deferred tax assets.
• Moderna guides 2026 revenue growth up to 10% and raises its year-end cash balance outlook to $4.7–$5.2 billion.
• Commercial and regulatory momentum includes Brazil collaboration for vaccines, EU joint procurement for up to 24 million doses of mRESVIA, approvals for mRESVIA in Australia and Mexico, approvals for mNEXSPIKE in Japan and Taiwan, and a VRBPAC consensus in favor of mFLUSIVA ahead of the August 5 PDUFA date in the U.S.

Financials in focus

Moderna’s quarterly top line sits in a modest lane, signaling that the company remains in a growth phase driven by a portfolio rather than a single blockbuster. The company reported total revenue of $145 million for Q2 2026, a hair above the $142 million seen in the prior-year quarter. The U.S. contributed $87 million of that total, with the remaining $58 million coming from international markets.

Cost of sales came in at $93 million, with notable drivers including a $41 million inventory write-down, $23 million of unutilized manufacturing capacity costs, and $11 million of third-party royalties. The company notes a roughly 22% year-over-year reduction in cost of sales, underscoring manufacturing productivity improvements and ongoing efficiency programs.

R&D spending remained substantial at $651 million, yet declined 7% versus the same period in 2025 as Moderna winds down several late-stage programs. SG&A was $216 million, a 6% decrease, reflecting ongoing discipline across the organization. Income taxes were not material, in line with a global valuation allowance against deferred tax assets.

Net loss for the quarter was about $0.8 billion, representing an improvement of roughly $43 million versus Q2 2025. The quarter’s earnings per share, on a GAAP basis, stood around $(1.97). The document’s later line on loss per share in the excerpt is incomplete, but the earlier figure helps frame the quarter’s profitability landscape.

Guidance matters: Moderna reiterates a plan for up to 10% revenue growth in 2026 and lifts its 2026 year-end cash balance target to a range of $4.7–$5.2 billion. These numbers imply that the firm remains focused on cash management and portfolio execution even as the story expands beyond a single vaccine cycle.

Commercial and regulatory momentum

The quarter’s narrative isn’t just about the math; it’s about pipeline execution and regulatory milestones that could move the line in a meaningful way. In commercial updates, Moderna highlighted a Brazil collaboration for vaccine supply and a European Union procurement contract with the European Commission for up to 24 million doses of mRESVIA across six countries. Regulatory progress includes approvals in Australia and Mexico for mRESVIA, and approvals in Japan and Taiwan for mNEXSPIKE. In the U.S., VRBPAC gave a unanimous or favorable recommendation for mFLUSIVA ahead of the August 5 PDUFA goal date, a potential inflection point for the company’s influenza vaccine portfolio.

These moves matter because they diversify Moderna’s revenue base and reduce dependence on any single product or geography. If mFLUSIVA clears the U.S. hurdle, the company could begin to see meaningful contribution from a multi-product mix, which would alter the revenue forecast trajectory and the volatility profile of the stock as regulatory calendars loom.

Implications for Moderna and its peers

Moderna’s Q2 results reflect a biotech cash flow reality: heavy up-front investment in R&D paired with a portfolio that is gradually converting science into scalable revenue. The cost discipline—particularly around inventory and capacity—already shows through the 22% YoY decline in cost of sales. If the company can sustain cost containment while advancing regulatory milestones, the path toward profitability becomes less a straight line and more a staircase with bigger steps when a product hits scale.

The regulatory calendar is a recurring theme for the sector. VRBPAC’s reception of mFLUSIVA and the August 5 PDUFA date in the U.S. could serve as a near-term catalyst, potentially lifting not just Moderna’s stock but the entire narrative around multi-product mRNA platforms. For Moderna’s peers, the message is clear: diversify beyond one- or two-shot franchises, build international partnerships, and align clinical milestones with manufacturing readiness to avoid the “one good quarter” syndrome.

On the earnings front, the presence of an EPS figure and a stated EPS consensus is important to watchers who crave a short-horizon read. The filing provides a GAAP EPS of approximately -$1.97 for the quarter, but it does not publish a defined EPS consensus or a formal earnings surprise number in the excerpt. Investors will likely weigh the quarter against guidance and pipeline progress, watching how the company converts the favorable regulatory chatter into actual revenue leverage over the next few quarters.

Conclusion: a regulated runway with a long-term runway

Moderna’s Q2 2026 results read as a disciplined, balance-sheet‑oriented chapter: meaningful top-line momentum is modest but stable, costs are trending down, and the portfolio is expanding against a backdrop of regulatory milestones that could unlock future revenue streams. The company’s forward-looking cash balance target suggests a cautious optimism about funding the next wave of product development without compromising liquidity.

For investors, the near-term catalysts are regulatory: the August 5 PDUFA date on mFLUSIVA and VRBPAC’s stance could reframe the quarterly narrative. For sector peers, Moderna’s approach — combining cost discipline with portfolio diversification and a proactive regulatory posture — offers a blueprint for turning early-stage science into a multi-product, geographically diversified business. If the plan to grow revenue by up to 10% in 2026 holds, the market may begin to reward a more balanced earnings trajectory that blends pipeline optionality with the economics of scaled manufacturing.